Patient Square Capital’s Ocular Therapeutix OCUL Stock Holding History

Patient Square Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-490,000	Closed	-$5.95M	–	34
2025 Q4	$5.95M	Sell	490,000 -225,000	-31%	-$2.73M	1.27%	19
2025 Q3	$8.36M	Sell	715,000 -102,699	-13%	-$1.23M	2.24%	9
2025 Q2	$7.59M	Sell	817,699 -102,500	-11%	-$802K	2.74%	6
2025 Q1	$6.75M	Buy	920,199 +449,280	+95%	+$3.45M	2.79%	5
2024 Q4	$4.02M	Buy	470,919 +235,421	+100%	+$2.3M	1.5%	10
2024 Q3	$2.05M	Buy	+235,498	New	+$1.94M	0.76%	10

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Patient Square Capital's OCUL Position: Q1 2026 in Review

Patient Square Capital sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 490,000 shares — an estimated $5.95M sold.

Patient Square Capital first reported a position in OCUL in Q3 2024 and held it in 6 quarters. The position peaked at $8.36M in Q3 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Patient Square Capital reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Patient Square Capital sold 490,000 Ocular Therapeutix shares in Q1 2026, an estimated $5.95M.
Patient Square Capital first reported a position in Ocular Therapeutix in Q3 2024 and held it in 6 quarters.
Patient Square Capital's Ocular Therapeutix position peaked at $8.36M in Q3 2025.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.